Preclinical contract research organization CRO for metabolic diseases - Physiogenex

Warning: A non-numeric value encountered in /home/physiogenex/www/physiogenex_www/wp-content/themes/Divi/functions.php on line 5841

The scientific focus adapted
to express the optimum potential
of your molecule

Marketing:
Unparalleled vision in metabolic disorders and risk assessment expertise for post-marketing studies and drug repositioning.

HeartArteryMacrophageLiverMusclePancreasAdipose Tissue

Preclinical development:
In-house predictive models and tracer technologies enable the generation of Proof of Concept efficacy data for your drugs.

Discovery:
Screening and lead validation utilize a dedicated research platform which combine with our focused scientific vision.

Home

Physiogenex is a preclinical contract research organization (CRO) that offers outstanding consultancy and research services, specializing inmetabolic disorders such as diabetes, obesity,liver diseases (NASH), dyslipidemia,atherosclerosis and cardiovascular complications.

More than just a CRO, we are your R&D partner of choice to target your specific needs. Our models and technologies are customized and we deliver unparalleled scientific expertise for R&D, preclinical development, post-marketing studies and drug repositioning. We also offer in vivo preclinical imaging services.

We provide both the biopharmaceutical and nutraceutical companies with optimal and reliable solutions for successful strategic decision-making.

R&D, Preclinical and Post marketing studies

Insulin resistance
OBESITY

LIVER DISEASES
NAFLD
Hepatic steatosis
to fibrosis

DYSLIPIDEMIA
ATHEROSCLEROSIS

DIABETIC
NEPHROPATHY

Animal models
from basic to predictive
in-house models

Experimental platform
From gold-standard to innovative assays

Scientific expertise and translational vision

News, Events and Publications

Physiogenex to present at the 3rd Paris NASH Symposium, July 6 & 7, 2017

Physiogenex presents the effects of SGLT2 inhibition and glucagon on intestinal cholesterol absorption at ADA 2017, San Diego, USA

Physiogenex and CLEA Japan Inc. present the benefits of SGLT2 inhibitor dapagliflozin on their 10-week rat model for evaluating drugs targeting Diabetic Nephropathy at ERA-EDTA 2017 congress in Madrid, Spain

Physiogenex and CLEA Japan Inc. present the benefits of SGLT2 inhibitor dapagliflozin on their 10-week rat model for evaluating drugs targeting Diabetic Nephropathy at EDNSG 2017 in Helsinki

Physiogenex and CLEA Japan Inc. present the benefits of SGLT2 inhibitor dapagliflozin on their 10-week rat model for evaluating drugs targeting Diabetic Nephropathy at the World Congress of Nephrology in Mexico

Physiogenex and Vaiomer will present new data dealing with the effects of obeticholic acid in the Diet-Induced NASH (DIN) hamster model at the AASLD ETC on NAFLD, in Washington, DC, USA, March 18-19, 2017.

Physiogenex will present the effects of obeticholic acid in its novel Diet-Induced NASH (DIN) hamster model at the Keystone Symposium on Bile Acid Receptors as Signal Integrators in Liver and Metabolism, in Monterey, CA, USA, March 3-7, 2017.

Physiogenex to present its 3-week NASH screening mouse model and the Diet-Induced NASH hamster model at the APASL 2017 in Shanghai.

Physiogenex to present its Diet-Induced NASH (DIN) hamster and Unx/salt-supplemented SDT fatty rat models at the World Congress on Insulin Resistance (WCIR) 2016

Physiogenex launches the Diet-Induced NASH (DIN) hamster, a unique model showing the same benefits and side effects of obeticholic acid observed in humans.